Vanguard Global Advisers
CRBP icon

Vanguard Global Advisers’s Corbus Pharmaceuticals CRBP Stock Holding History

Vanguard Global Advisers’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44K Hold
4,695
– – ﹤0.01% 3114
2026
Q1 		$44.1K Buy
+4,695
New +$39.5K ﹤0.01% 3077

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $214M AUM 88.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Global Advisers's CRBP Position: Q2 2026 in Review

Vanguard Global Advisers held its Corbus Pharmaceuticals (CRBP) position steady in Q2 2026 at 4,695 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #3114.

Vanguard Global Advisers first reported a position in CRBP in Q1 2026 and has held it in 2 quarters since. The position peaked at $44.1K in Q1 2026. 107 funds tracked by Wall St. Rank hold CRBP as of Q2 2026.

  • Vanguard Global Advisers held 4,695 shares of Corbus Pharmaceuticals worth $44K as of Q2 2026.
  • Vanguard Global Advisers left its Corbus Pharmaceuticals share count unchanged in Q2 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3114 holding.
  • Vanguard Global Advisers first reported a position in Corbus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Corbus Pharmaceuticals position peaked at $44.1K in Q1 2026.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.